Report Overview

The Australian Anti-Fungal Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Fungal infections represent the invasion of tissues by one or more species of fungi. They range from superficial, localized skin conditions to deeper tissue infections to serious lung, blood (septicemia), or systemic diseases. Some fungi are opportunistic while others are pathogenic, causing disease whether the immune system is healthy or not. Histoplasmosis, caused by Histoplasma capsulatum is a rare disease in Australia and most cases have been associated with visiting bat caves. It typically affects the lungs. Blastomycosis, caused by Blastomyces dermatitidis and Coccidiomycosis, caused primarily by Coccidioides immitis cannot be acquired in Australia but may occur in people who have traveled to regions of North America where these fungi are found. Fungal infections include both systemic and superficial infections such as infections of the skin, eye, mouth, and vagina. Antifungal products with fungicidal activity are mostly used to treat a wide array of diseases, such as athlete's foot, ringworm, and fungal meningitis, caused by fungal agents.



Market Drivers

The major factors augmenting the growth of the anti-fungal drugs market include increasing awareness about the myriad fungal infections, increasing the number of antifungal drugs available over the counter (OTC), and rising consumption of anti-fungal drugs in developing regions for a variety of medical conditions.

With the rising popularity of over-the-counter (OTC) drugs, many patients prefer OTC drugs over obtaining a prescription from a healthcare professional. Numerous common and harmless fungal infections are left untreated by patients, owing to medical costs and logistical constraints. These have directly contributed to the rise in the usage of OTC drugs, as these infections can be treated by OTC drugs, owing to their ease of availability. The increased usage of OTC drugs has further contributed to the rise in anti-fungal drug sales over the years. Besides, the anti-fungal drugs market is expected to grow at a steady pace owing to the rising research and development activities.

Epidemiology

Candidemia is a common invasive fungal infection with a high mortality rate. In Western Australia, 2005-2014. There were 167 episodes of candidemia due to 173 isolates of Candida. Candida albicans (40.5%), Candida glabrata complex (30.6%), Candida parapsilosis complex (14.4%) were the most common species causing candidemia across the study. Of the tested isolates, 17.7% (11/62) were non-susceptible to fluconazole and 13.6% (9/66) non-susceptible to caspofungin. 22.8% (8/35) C. glabrata complex were fluconazole resistant and 17.1% (6/35) were non-susceptible to caspofungin.